dndn q3 result

http://investor.dendreon.com/releasedetail.cfm?ReleaseID=620325

Recent Highlights:

•Announced approximately $66 million in gross PROVENGE sales in the third quarter.
•At the end of the third quarter, more than 680 total sites have completed the in servicing process, of which:
?More than 425 sites have infused PROVENGE; and
?Approximately 470 sites have either infused the product or have their patients scheduled for their first PROVENGE regimen.
•Awareness of the National Coverage Decision (NCD), issued by the Centers of Medicare and Medicaid Services, and Q-code grew from 25% in July to approximately 70% in September.
•Reported average time to payment is approximately 30 days for physicians, reflecting an improved reimbursement landscape due to a national coverage decision and activation of a Q-code that accelerates electronic adjudication of claims.
•Received FDA approval of its Atlanta manufacturing facility in August.
......

Revenue up from $49.6mil in Q2 to $66mil in Q3, approx 33%;
Awareness of NCD from approx 25% in Q2 to 70% in Q3;

It looks like Dendreon started to get their hands/heads together with their sales/marketing dept. Hopefully this in time progress annoucement of DNDN could bring in extra positive theme to our PRR's AGM today.